GlassScriptPhysician profile
David Keith Wilson
NPI 1972533396
$6,086.80
in general payments reported to CMS, 2019-2025
32 companies · $1,969 in 2025
The $1,969 reported for 2025 was more than what 95% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.84 · 2020: $15.09 · 2021: $240 · 2022: $906 · 2023: $1,458 · 2024: $1,486 · 2025: $1,969.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,894 · Education: $18.85.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,894.18 |
| Education | $18.85 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $970.35 | 2021-2025 | Repatha, Otezla, Repatha |
| Astrazeneca Pharmaceuticals LP | $940.83 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Novo Nordisk INC | $889.93 | 2019-2025 | Ozempic, Rybelsus, Saxenda |
| Glaxosmithkline, LLC. | $495.59 | 2022-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merz North America, INC. | $349.29 | 2022-2023 | Xeomin |
| Lilly USA, LLC | $295.11 | 2023-2025 | Mounjaro, Zepbound, Jardiance |
| Lundbeck LLC | $279.07 | 2020-2025 | Rexulti |
| Abbvie INC. | $247.24 | 2022-2025 | Vraylar |
| Pfizer INC. | $220.70 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $213.77 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $160.47 | 2021-2024 | Trintellix |
| Exact Sciences Corporation | $148.50 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Astellas Pharma US INC | $147.36 | 2023-2025 | Veozah |
| Otsuka America Pharmaceutical, INC. | $108.71 | 2023-2025 | Rexulti, Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $81.78 | 2023-2025 | Ofev, Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $63.64 | 2024-2025 | Zenpep |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.45 | 2023-2024 | Xifaxan |
| Hologic Sales and Service, LLC | $46.95 | 2022-2025 | Aptima |
| Phathom Pharmaceuticals, INC. | $46.26 | 2024-2025 | Voquezna |
| Noven Therapeutics, LLC | $45.57 | 2024 | Xelstrym, Secuado |
| Corcept Therapeutics | $38.08 | 2025 | Korlym |
| Ibsa Pharma INC. | $37.72 | 2021-2023 | Tirosint, Licart |
| Janssen Pharmaceuticals, INC | $28.88 | 2021-2022 | |
| Alkermes, INC. | $27.89 | 2024 | Vivitrol |
| Abiomed | $22.72 | 2025 | |
| Idorsia Pharmaceuticals US INC | $21.85 | 2023 | Quviviq |
| Novartis Pharmaceuticals Corporation | $17.37 | 2022 | |
| Sanofi-Aventis U.S. LLC | $17.17 | 2023 | |
| Philips North America LLC | $16.98 | 2022 | |
| Esperion Therapeutics, INC. | $16.49 | 2023 | Nexletol |
| Kowa Pharmaceuticals America, INC. | $16.21 | 2025 | Zoryve |
| Stryker Corporation | $14.87 | 2025 | Na |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Wilson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.